OPKO Health

OPK · NASDAQ

$1.66+$0.05 (+3.11%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $1.61

Latest news

NewsOct 20, 12:37 PM ETVandana Singh
Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp
NewsOct 16, 10:09 AM ETAvi Kapoor
Ladder Capital Posts Upbeat Q3 Earnings, Joins Alcoa, Hyster-Yale And Other Big Stocks Moving Higher On Friday
NewsOct 15, 1:22 PM ETAvi Kapoor
Crude Oil Moves Higher; Charles Schwab Shares Fall After Q3 Results
NewsOct 15, 11:41 AM ETVandana Singh
OPKO Health Sheds Diagnostics Businesses in Major Labcorp Deal
Press releaseOct 15, 7:30 AM ETPRNewswire
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health
Press releaseAug 13, 9:15 AM ETGlobe Newswire
OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests
Press releaseAug 3, 7:00 AM ETGlobe Newswire
Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health
NewsJul 28, 1:06 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
NewsJul 28, 12:28 PM ETAvi Kapoor
Crude Oil Down Over 5%; Boeing Shares Rise After Q2 Results
NewsJul 28, 5:01 AM ETAvi Kapoor
Why Celestica Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
NewsJul 27, 5:06 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
Press releaseJul 27, 4:05 PM ETGlobe Newswire
OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results
Press releaseJun 16, 8:33 AM ETGlobe Newswire
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
Press releaseJun 15, 8:00 AM ETGlobe Newswire
Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026
Press releaseMay 12, 8:00 AM ETGlobe Newswire
OPKO Health's ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies
NewsApr 30, 8:32 AM ET
OPKO Health Subsidiary EirGen Pharma Expands Agreement With Nicoya Therapeutics To Commercialize RAYALDEE In China
Press releaseApr 30, 8:30 AM ETGlobe Newswire
OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China
NewsApr 29, 4:34 AM ET
OPKO Health Q1 2026 Earnings Call: Complete Transcript
NewsApr 28, 7:11 AM ET
Earnings Scheduled For April 28, 2026
NewsFeb 26, 4:19 PM ET
Earnings Breakdown: OPKO Health Q4
NewsFeb 26, 4:13 PM ET
OPKO Health Q4 EPS $(0.04) Beats $(0.07) Estimate, Sales $148.500M Beat $139.757M Estimate
Press releaseNov 13, 8:03 AM ETPRNewswire
NextPlat Reports Third Quarter 2025 Results
Press releaseSep 15, 8:30 AM ETPRNewswire
Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses
NewsJul 31, 5:07 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
Press releaseJun 30, 8:01 AM ETPRNewswire
NextPlat Issues Interim CEO Update Shareholder Letter
NewsApr 25, 3:00 PM ET
Analyst Expectations For OPKO Health's Future
Press releaseApr 11, 4:05 PM ETPRNewswire
NextPlat Provides Statement on U.S. Tariff Impact on its E-Commerce Development Program
NewsApr 7, 2:00 PM ET
OPKO Health Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
NewsMar 19, 8:00 AM ET
Forecasting The Future: 6 Analyst Projections For OPKO Health
Press releaseMar 11, 7:00 AM ETPRNewswire
Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses
Press releaseDec 10, 8:00 AM ETPRNewswire
NextPlat Gains e-Commerce Access to Over 340 Million Consumers with Launch on JD.Com, China's Largest Online Retailer
Press releaseNov 18, 8:00 AM ETPRNewswire
NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo
Press releaseNov 14, 6:00 AM ETPRNewswire
NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024, Representing a 136% Increase Over 2023 Results
Press releaseNov 7, 4:05 PM ETGlobe Newswire
OPKO Health Reports Third Quarter 2024 Business Highlights and Financial Results
Press releaseOct 7, 8:00 AM ETPRNewswire
NextPlat Secures Four-Year Extension of OPKO Healthcare E-Commerce Program in China and Agrees to the Expansion of the Program into Japan
NewsSep 17, 11:00 AM ET
Analyst Scoreboard: 4 Ratings For OPKO Health
Press releaseSep 16, 7:30 AM ETPRNewswire
Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health
NewsJul 18, 11:13 AM ETErica Kollmann
Opko Health Stock Is Climbing: What's Going On?
NewsJul 18, 10:29 AM ETAvi Kapoor
Cintas Posts Upbeat Earnings, Joins CommScope Holding, Virtu Financial And Other Big Stocks Moving Higher On Thursday
NewsJul 17, 5:31 PM ETErica Kollmann
Why Opko Health Shares Are Up After-Hours

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp

Ladder Capital Posts Upbeat Q3 Earnings, Joins Alcoa, Hyster-Yale And Other Big Stocks Moving Higher On Friday

Crude Oil Moves Higher; Charles Schwab Shares Fall After Q3 Results

OPKO Health Sheds Diagnostics Businesses in Major Labcorp Deal

Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health

OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health

12 Health Care Stocks Moving In Tuesday's Intraday Session

Crude Oil Down Over 5%; Boeing Shares Rise After Q2 Results

Why Celestica Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Monday's After-Market Session

OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026

Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026

OPKO Health's ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies

OPKO Health Subsidiary EirGen Pharma Expands Agreement With Nicoya Therapeutics To Commercialize RAYALDEE In China

OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China

OPKO Health Q1 2026 Earnings Call: Complete Transcript

Earnings Scheduled For April 28, 2026

Earnings Breakdown: OPKO Health Q4

OPKO Health Q4 EPS $(0.04) Beats $(0.07) Estimate, Sales $148.500M Beat $139.757M Estimate

NextPlat Reports Third Quarter 2025 Results

Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

12 Health Care Stocks Moving In Thursday's After-Market Session

NextPlat Issues Interim CEO Update Shareholder Letter

Analyst Expectations For OPKO Health's Future

NextPlat Provides Statement on U.S. Tariff Impact on its E-Commerce Development Program

OPKO Health Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)

Forecasting The Future: 6 Analyst Projections For OPKO Health

Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

NextPlat Gains e-Commerce Access to Over 340 Million Consumers with Launch on JD.Com, China's Largest Online Retailer

NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo

NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024, Representing a 136% Increase Over 2023 Results

OPKO Health Reports Third Quarter 2024 Business Highlights and Financial Results

NextPlat Secures Four-Year Extension of OPKO Healthcare E-Commerce Program in China and Agrees to the Expansion of the Program into Japan

Analyst Scoreboard: 4 Ratings For OPKO Health

Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health

Opko Health Stock Is Climbing: What's Going On?

Cintas Posts Upbeat Earnings, Joins CommScope Holding, Virtu Financial And Other Big Stocks Moving Higher On Thursday

Why Opko Health Shares Are Up After-Hours